Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma

Darshil J. Shah, Roxana S Dronca

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Melanoma is the most dangerous form of skin cancer owing to its metastatic potential and is an important public health concern. The melanoma incidence has been increasing worldwide. Although potentially curable when diagnosed early, metastatic melanoma carries a poor prognosis. Until recently, systemic therapy for metastatic melanoma was ineffective, but the recent successes in the development of new therapies for metastatic melanoma, such as mitogen-activated protein kinase (MAPK) pathway inhibitors, antiecytotoxic T-lymphocyteeassociated antigen-4 (CTLA-4), and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blocking antibodies, as well as combination strategies of cytotoxic chemotherapy and inhibitors of angiogenesis, have all yielded promising results, changing the continually evolving landscape of therapeutic options for patients with this disease. The aim of this review was to summarize the evolution of and recent advances in the treatment of metastatic melanoma. Therefore, we conducted a comprehensive PubMed search between January 1, 1960, and February 1, 2014, using the search term melanoma or metastatic melanoma combined with terms such as chemotherapy, immunotherapy, CTLA-4, PD-1, PD-L1, adoptive T cell, targeted therapy, MAPK, molecular biology, and survival.

Original languageEnglish (US)
Pages (from-to)504-519
Number of pages16
JournalMayo Clinic Proceedings
Volume89
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Melanoma
CD274 Antigen
Therapeutics
Mitogen-Activated Protein Kinases
Programmed Cell Death 1 Receptor
Drug Therapy
Blocking Antibodies
Angiogenesis Inhibitors
Viral Tumor Antigens
Skin Neoplasms
Protein Kinase Inhibitors
Cell- and Tissue-Based Therapy
PubMed
Immunotherapy
Molecular Biology
Public Health
T-Lymphocytes
Survival
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. / Shah, Darshil J.; Dronca, Roxana S.

In: Mayo Clinic Proceedings, Vol. 89, No. 4, 2014, p. 504-519.

Research output: Contribution to journalArticle

@article{50d418e8c0cb4488bcfc4655cfe7da6d,
title = "Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma",
abstract = "Melanoma is the most dangerous form of skin cancer owing to its metastatic potential and is an important public health concern. The melanoma incidence has been increasing worldwide. Although potentially curable when diagnosed early, metastatic melanoma carries a poor prognosis. Until recently, systemic therapy for metastatic melanoma was ineffective, but the recent successes in the development of new therapies for metastatic melanoma, such as mitogen-activated protein kinase (MAPK) pathway inhibitors, antiecytotoxic T-lymphocyteeassociated antigen-4 (CTLA-4), and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blocking antibodies, as well as combination strategies of cytotoxic chemotherapy and inhibitors of angiogenesis, have all yielded promising results, changing the continually evolving landscape of therapeutic options for patients with this disease. The aim of this review was to summarize the evolution of and recent advances in the treatment of metastatic melanoma. Therefore, we conducted a comprehensive PubMed search between January 1, 1960, and February 1, 2014, using the search term melanoma or metastatic melanoma combined with terms such as chemotherapy, immunotherapy, CTLA-4, PD-1, PD-L1, adoptive T cell, targeted therapy, MAPK, molecular biology, and survival.",
author = "Shah, {Darshil J.} and Dronca, {Roxana S}",
year = "2014",
doi = "10.1016/j.mayocp.2014.02.002",
language = "English (US)",
volume = "89",
pages = "504--519",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma

AU - Shah, Darshil J.

AU - Dronca, Roxana S

PY - 2014

Y1 - 2014

N2 - Melanoma is the most dangerous form of skin cancer owing to its metastatic potential and is an important public health concern. The melanoma incidence has been increasing worldwide. Although potentially curable when diagnosed early, metastatic melanoma carries a poor prognosis. Until recently, systemic therapy for metastatic melanoma was ineffective, but the recent successes in the development of new therapies for metastatic melanoma, such as mitogen-activated protein kinase (MAPK) pathway inhibitors, antiecytotoxic T-lymphocyteeassociated antigen-4 (CTLA-4), and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blocking antibodies, as well as combination strategies of cytotoxic chemotherapy and inhibitors of angiogenesis, have all yielded promising results, changing the continually evolving landscape of therapeutic options for patients with this disease. The aim of this review was to summarize the evolution of and recent advances in the treatment of metastatic melanoma. Therefore, we conducted a comprehensive PubMed search between January 1, 1960, and February 1, 2014, using the search term melanoma or metastatic melanoma combined with terms such as chemotherapy, immunotherapy, CTLA-4, PD-1, PD-L1, adoptive T cell, targeted therapy, MAPK, molecular biology, and survival.

AB - Melanoma is the most dangerous form of skin cancer owing to its metastatic potential and is an important public health concern. The melanoma incidence has been increasing worldwide. Although potentially curable when diagnosed early, metastatic melanoma carries a poor prognosis. Until recently, systemic therapy for metastatic melanoma was ineffective, but the recent successes in the development of new therapies for metastatic melanoma, such as mitogen-activated protein kinase (MAPK) pathway inhibitors, antiecytotoxic T-lymphocyteeassociated antigen-4 (CTLA-4), and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blocking antibodies, as well as combination strategies of cytotoxic chemotherapy and inhibitors of angiogenesis, have all yielded promising results, changing the continually evolving landscape of therapeutic options for patients with this disease. The aim of this review was to summarize the evolution of and recent advances in the treatment of metastatic melanoma. Therefore, we conducted a comprehensive PubMed search between January 1, 1960, and February 1, 2014, using the search term melanoma or metastatic melanoma combined with terms such as chemotherapy, immunotherapy, CTLA-4, PD-1, PD-L1, adoptive T cell, targeted therapy, MAPK, molecular biology, and survival.

UR - http://www.scopus.com/inward/record.url?scp=84898639033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898639033&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2014.02.002

DO - 10.1016/j.mayocp.2014.02.002

M3 - Article

C2 - 24684873

AN - SCOPUS:84898639033

VL - 89

SP - 504

EP - 519

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -